Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Drews

Showing results (131-140 of 179) with videos related to

Pageof 18
Sort By:
Access Microbiology|December 11, 2023
Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccinationMichael Asamoah-Boaheng, Brian Grunau, Scott Haig, et al.
Microbiology Spectrum|June 8, 2023
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021Yi-Chan J Lin, David H Evans, Ninette F Robbins, et al.
Microbiology Spectrum|January 10, 2023
Cross-Canada Variability in Blood Donor SARS-CoV-2 Seroprevalence by Social Determinants of HealthSheila F O'Brien, Niamh Caffrey, Qi-Long Yi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2018
Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010-2016Annette K Regan, Nicola P Klein, Gayle Langley, et al.
Open Forum Infectious Diseases|September 29, 2018
Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?Catharine Chambers, Danuta M Skowronski, Caren Rose, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 17, 2017
Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017Danuta M Skowronski, Catharine Chambers, Suzana Sabaiduc, et al.
Microbiology Spectrum|March 7, 2022
Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273Brian Grunau, Liam Golding, Martin A Prusinkiewicz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 31, 2016
A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 SeasonDanuta M Skowronski, Catharine Chambers, Suzana Sabaiduc, et al.
Annals of Emergency Medicine|April 24, 2022
A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 PandemicBrian Grunau, Sheila F O'Brien, Tracy L Kirkham, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 8, 2018
Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018Danuta M Skowronski, Catharine Chambers, Gaston De Serres, et al.
Pageof 18

Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
Access Microbiology|December 11, 2023
Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccinationMichael Asamoah-Boaheng, Brian Grunau, Scott Haig, et al.
Microbiology Spectrum|June 8, 2023
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021Yi-Chan J Lin, David H Evans, Ninette F Robbins, et al.
Microbiology Spectrum|January 10, 2023
Cross-Canada Variability in Blood Donor SARS-CoV-2 Seroprevalence by Social Determinants of HealthSheila F O'Brien, Niamh Caffrey, Qi-Long Yi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2018
Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010-2016Annette K Regan, Nicola P Klein, Gayle Langley, et al.
Open Forum Infectious Diseases|September 29, 2018
Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?Catharine Chambers, Danuta M Skowronski, Caren Rose, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 17, 2017
Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017Danuta M Skowronski, Catharine Chambers, Suzana Sabaiduc, et al.
Microbiology Spectrum|March 7, 2022
Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273Brian Grunau, Liam Golding, Martin A Prusinkiewicz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 31, 2016
A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 SeasonDanuta M Skowronski, Catharine Chambers, Suzana Sabaiduc, et al.
Annals of Emergency Medicine|April 24, 2022
A Prospective Observational Cohort Comparison of SARS-CoV-2 Seroprevalence Between Paramedics and Matched Blood Donors in Canada During the COVID-19 PandemicBrian Grunau, Sheila F O'Brien, Tracy L Kirkham, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 8, 2018
Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018Danuta M Skowronski, Catharine Chambers, Gaston De Serres, et al.
Pageof 18